Literature DB >> 2690285

Vaccination against enteric bacterial diseases.

D Hone1, J Hackett.   

Abstract

We review evidence that the systemic and mucosal immune systems of the body are compartmentalized. The development of immunity against an antigen at one mucosal surface may lead to the appearance of that immunity at other mucosal surfaces. In order to attain good protective immunity against a bacterial enteropathogen, it may be necessary to induce such immunity through the mucosal immune system of the gut. Earlier attempts to elicit protective immunity against bacterial enteropathogens by parenteral vaccination are reviewed. The modern approach involves oral administration of antigen. Such antigen may consist of killed bacteria or--more effectively--live, attenuated bacteria bearing antigens of interest. Such bacteria may be enteropathogens attenuated by mutation, either general or site-directed, or hybrid strains in which a bacterial carrier expresses an antigenic determinant of interest from cloned DNA. While good progress has been made in the comprehension of the requirements for effective vaccination against enteropathogenic bacteria, future work will produce more effective carrier strains than are currently available.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2690285     DOI: 10.1093/clinids/11.6.853

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  5 in total

1.  Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.

Authors:  A B Hartman; L L Van de Verg; H H Collins; D B Tang; N O Bendiuk; D N Taylor; C J Powell
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

Review 2.  Pathogenesis of Helicobacter pylori infection.

Authors:  Johannes G Kusters; Arnoud H M van Vliet; Ernst J Kuipers
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

3.  Mucosal immune response to RDEC-1 infection: study of lamina propria antibody-producing cells and biliary antibody.

Authors:  C E McQueen; E C Boedeker; M Le; Y Hamada; W R Brown
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

4.  Mutations at rfc or pmi attenuate Salmonella typhimurium virulence for mice.

Authors:  L V Collins; S Attridge; J Hackett
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

Review 5.  Flavodoxins as Novel Therapeutic Targets against Helicobacter pylori and Other Gastric Pathogens.

Authors:  Sandra Salillas; Javier Sancho
Journal:  Int J Mol Sci       Date:  2020-03-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.